{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:24:08Z","timestamp":1788607448710,"version":"build-2803163510"},"reference-count":13,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jtocrr.2025.100807","type":"journal-article","created":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T00:21:23Z","timestamp":1739492483000},"page":"100807","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Combination of Lurbinectedin and Osimertinib for Treatment of EGFR-Mutated Transformed SCLC: A Brief Report"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9937-7048","authenticated-orcid":false,"given":"Aditi","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthi","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aastha","family":"Poddar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Dimou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaushal","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Shanshal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Schwecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Moffett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron S.","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Leventakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2025.100807_bib1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2025.100807_bib2","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","article-title":"Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer","volume":"121","author":"Leonetti","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtocrr.2025.100807_bib3","doi-asserted-by":"crossref","DOI":"10.1177\/17588359221130503","article-title":"Histologic transformation in lung cancer: when one door shuts, another opens","volume":"14","author":"Sato","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.jtocrr.2025.100807_bib4","article-title":"A challenging case of stage IV EGFR-mutant lung cancer with histologic transformation and multiple resistance mechanisms. Current Problems in Cancer","volume":"13","author":"Rivera-Concepcion","year":"2024","journal-title":"Case Rep"},{"key":"10.1016\/j.jtocrr.2025.100807_bib5","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1016\/j.jtho.2019.06.002","article-title":"Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes","volume":"14","author":"Offin","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtocrr.2025.100807_bib6","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1158\/2159-8290.CD-20-1863","article-title":"Multiomic analysis of lung tumors defines pathways activated in neuroendocrine transformation","volume":"11","author":"Quintanal-Villalonga","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtocrr.2025.100807_bib7","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1200\/JCO.18.01585","article-title":"EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes","volume":"37","author":"Marcoux","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2025.100807_bib8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.lungcan.2022.11.016","article-title":"A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival","volume":"175","author":"Zhang","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtocrr.2025.100807_bib9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtocrr.2025.100807_bib10","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1158\/1078-0432.CCR-23-0471","article-title":"De novo and histologically transformed small-cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways","volume":"29","author":"Chakraborty","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2025.100807_bib11","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.cllc.2023.09.001","article-title":"Real-world outcomes with lurbinectedin in second-line setting and beyond for extensive stage small cell lung cancer","volume":"24","author":"Desai","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtocrr.2025.100807_bib12","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/S2213-2600(22)00309-5","article-title":"Combination lurbinectedin and doxorubicin versus physician\u2019s choice of chemotherapy in patients with relapsed small-cell lung cancer (Atlantis): a multicentre, randomised, open-label, phase 3 trial","volume":"11","author":"Aix","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jtocrr.2025.100807_bib13","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.canlet.2012.12.028","article-title":"Advances for studying clonal evolution in cancer","volume":"340","author":"Ding","year":"2013","journal-title":"Cancer Lett"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364325000232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364325000232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T15:40:50Z","timestamp":1748965250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364325000232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2666364325000232"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2025.100807","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of Lurbinectedin and Osimertinib for Treatment of EGFR-Mutated Transformed SCLC: A Brief Report","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2025.100807","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"100807"}}